Clearview Cancer Institute has a nationally accredited program for peripheral blood stem cell transplant. Established in 1998, this program was one of the first 100 transplant programs in the United States to receive the national accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT).

Peripheral Blood Stem Cell Transplant (PBSCT) is a treatment option which may be used for some patients with:

• Leukemia
• Non-Hodgkin’s Lymphoma
• Hodgkin’s Lymphoma
• Multiple Myeloma
• Amyloidosis

After a patient receives initial treatment for cancer, higher doses of chemotherapy (HDC) with stem cell transplant may be the best option for a cure. Normally, PBSCT occurs in several steps.

» Step 1. The patient undergoes evaluation for eligibility for the transplant procedure.

» Step 2. Stem cells are collected from the patient’s own blood system and stored in a frozen state. These stem cells are the cells are killed after the HDC and are necessary to produce the blood components of red blood cells, white blood cells, and platelets.

» Step 3. High doses of chemotherapy are given to kill the cancer cells.

» Step 4. Stem cells are thawed and infused back into the patient.

Usually 10-14 days later these infused stem cells begin producing mature red blood cells, white blood cells, and platelets.